L'Hopital Prive Du Confluent

The oncology department at L'Hopital Prive Du Confluent also supports cardiovascular research, focusing on patients with atrial fibrillation who are at risk of stroke and systemic embolism. The trials aim to compare new oral anticoagulants with standard therapy to improve safety and reduce clot‑related events.

• Comparative effectiveness of novel anticoagulants versus established agents
• Evaluation of bleeding risk using international safety criteria
• Biomarker‑driven patient stratification for personalized anticoagulation
• Long‑term outcomes on stroke prevention in high‑risk populations

These studies underline the site’s commitment to integrating cardiovascular care within its broader oncology mission.

Clinical investigations at the Nantes facility address malignancies of the digestive tract, including colon carcinoma and hepatocellular carcinoma. Researchers evaluate new systemic agents and immunotherapy combinations to prolong survival and achieve higher response rates in advanced disease.

• Targeted therapy trials for liver cancer
• Immunotherapy plus chemotherapy regimens for colorectal tumors
• Assessment of radiographic progression‑free survival as primary endpoint
• Exploration of predictive biomarkers for treatment selection

The program reflects a multidisciplinary effort to improve outcomes for patients with gastrointestinal cancers.

The site conducts studies on advanced prostate malignancies, notably high‑risk metastatic hormone‑sensitive prostate cancer. Trials test combinations of hormonal agents such as abiraterone with novel compounds to enhance radiographic progression‑free survival and delay disease progression.

• Combination hormone therapy with androgen‑axis inhibitors
• Integration of CDK4/6 inhibitors into prostate cancer treatment
• Safety and tolerability profiling of emerging oral agents
• Evaluation of quality‑of‑life endpoints alongside efficacy

These efforts aim to broaden therapeutic options for men facing aggressive urogenital cancers.

A diverse portfolio of oncology trials targets solid tumors such as non‑small cell lung cancer, ER+/HER2‑ negative breast cancer, triple‑negative breast cancer, ovarian and endometrial cancers, and head‑and‑neck squamous cell carcinoma. The central goal is to test innovative immunotherapy‑based regimens and targeted agents to improve survival and reduce recurrence.

• Immune checkpoint inhibitor combinations with chemotherapy
• Adjuvant and neoadjuvant strategies to prevent disease relapse
• Antibody‑drug conjugates evaluated for first‑line therapy
• Biomarker‑guided personalized treatment pathways

L'Hopital Prive Du Confluent leverages its oncology expertise to advance cancer care across multiple disease sites.

One of the ongoing studies addresses chronic pain, specifically chronic coccygodynia, using high‑concentration topical analgesics. The trial evaluates the efficacy and safety of capsaicin 8% patches to provide long‑lasting relief for patients with persistent sacral discomfort.

• Randomized, double‑blind assessment of capsaicin patch effectiveness
• Patient‑reported outcome measures for pain reduction
• Safety monitoring for local and systemic adverse events
• Long‑term follow‑up to gauge durability of pain relief

This research highlights the site’s dedication to improving symptom management alongside cancer treatment.

The facility’s research program emphasizes modulation of the immune response in cancer therapy, featuring agents such as pembrolizumab and the antibody‑drug conjugate datopotamab deruxtecan. Studies aim to enhance antitumor immunity, assess response durability, and explore synergistic effects with other targeted drugs.

• Combination immunotherapy trials with checkpoint inhibitors
• Evaluation of novel antibody‑drug conjugates in solid tumors
• Immune‑related response criteria and biomarker analyses
• Safety and efficacy of adding immune modulators to standard regimens

These investigations position L'Hopital Prive Du Confluent at the forefront of immune‑focused cancer research in Europe.